Prospective evaluation of alternative donor from unrelated donor and cord blood in adult acute leukemia and myelodysplastic syndrome.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
20
01
2020
accepted:
02
03
2020
revised:
28
02
2020
pubmed:
24
3
2020
medline:
22
6
2021
entrez:
24
3
2020
Statut:
ppublish
Résumé
A prospectively registered observational study was conducted to assess the significance of allogeneic hematopoietic stem cell transplantation from highly HLA-matched unrelated donors (UD) and cord blood (CB) on outcomes in adult acute leukemia (AL) and myelodysplastic syndrome (MDS). Between 2007 and 2015, 231 transplant-eligible patients were registered for a phase 2 study of alternative donor transplantation. After registration, a sufficient time period was given to find appropriate UD. Patients received CB transplantation (CBT) if an appropriate UD was unavailable. In total, 119 patients received CBT (106 AL and 13 MDS) and 91 patients received UD transplantation (UDT) (86 AL and 5 MDS). The median age was 39 years in both groups. The primary objective was overall survival (OS); secondary objectives included cumulative incidences of non-relapse mortality (NRM) and relapse, and disease-free survival. Diagnosis, disease status at transplantation, refined disease risk index, and hematopoietic cell transplant-specific comorbidity index did not differ between UDT and CBT. In multivariate analyses, graft source was not a significant risk factor for all objectives. In adjusted analyses, UDT and CBT showed similar OS, NRM, and relapse in this prospective study. CB can be a comparable alternative stem cell source to UD by achieving a timely transplant.
Identifiants
pubmed: 32203259
doi: 10.1038/s41409-020-0859-8
pii: 10.1038/s41409-020-0859-8
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1399-1409Références
Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N. Engl J Med. 2004;351:2276–85.
doi: 10.1056/NEJMoa041469
Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N. Engl J Med. 2004;351:2265–75.
doi: 10.1056/NEJMoa041276
Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013;122:491–8.
doi: 10.1182/blood-2013-02-453175
Atsuta Y, Morishima Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, et al. Comparison of unrelated cord blood transplantation and HLA-mismatched unrelated bone marrow transplantation for adults with leukemia. Biol Blood Marrow Transplant. 2012;18:780–7.
doi: 10.1016/j.bbmt.2011.10.008
Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010;11:653–60.
doi: 10.1016/S1470-2045(10)70127-3
Spellman SR, Eapen M, Logan BR, Mueller C, Rubinstein P, Setterholm MI, et al. A perspective on the selection of unrelated donors and cord blood units for transplantation. Blood. 2012;120:259–65.
doi: 10.1182/blood-2012-03-379032
Terakura S, Atsuta Y, Tsukada N, Kobayashi T, Tanaka M, Kanda J, et al. Comparison of outcomes of 8/8 and 7/8 allele-matched unrelated bone marrow transplantation and single-unit cord blood transplantation in adults with acute leukemia. Biol Blood Marrow Transplant. 2016;22:330–8.
doi: 10.1016/j.bbmt.2015.10.006
Ustun C, Giannotti F, Zhang MJ, Wang HL, Brunstein C, Labopin M, et al. Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis. Leukemia. 2017;31:1408–14.
doi: 10.1038/leu.2017.42
Barker JN, Krepski TP, DeFor TE, Davies SM, Wagner JE, Weisdorf DJ. Searching for unrelated donor hematopoietic stem cells: availability and speed of umbilical cord blood versus bone marrow. Biol Blood Marrow Transplant. 2002;8:257–60.
doi: 10.1053/bbmt.2002.v8.pm12064362
Kawashima N, Nishiwaki S, Shimizu N, Kamoshita S, Watakabe K, Yokohata E, et al. Outcomes of strategic alternative donor selection or suspending donor search based on Japan Marrow Donor Program coordination status. Int J Hematol. 2018;107:551–8.
doi: 10.1007/s12185-018-2413-7
Terakura S, Nishida T, Sawa M, Kato T, Miyao K, Ozawa Y, et al. Prospective phase 2 study of umbilical cord blood transplantation in adult acute leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2020;26:139–144. https://doi.org/10.1016/j.bbmt.2019.09.021 .
doi: 10.1016/j.bbmt.2019.09.021
pubmed: 31546004
Sorror M, Maris M, Storb R, Baron F, Sandmaier B, Maloney D, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.
doi: 10.1182/blood-2005-05-2004
Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–71.
doi: 10.1182/blood-2014-01-552984
Bray RA, Hurley CK, Kamani NR, Woolfrey A, Muller C, Spellman S, et al. National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. Biol Blood Marrow Transplant. 2008;14:45–53.
doi: 10.1016/j.bbmt.2008.06.014
Dehn J, Spellman S, Hurley CK, Shaw BE, Barker JN, Burns LJ, et al. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Blood. 2019;134:924–34.
doi: 10.1182/blood.2019001212
Przepiorka D, Weisdorf D, Martin P, Klingemann H, Beatty P, Hows J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.
pubmed: 7581076
Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–33.
doi: 10.1053/bbmt.2003.50026
Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
doi: 10.1080/01621459.1958.10501452
Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.
doi: 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
doi: 10.1080/01621459.1999.10474144
Cox DR. Regression models and life-tables. J R Stat Soc Ser B. 1972;34:187–220.
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
doi: 10.1038/bmt.2012.244
Elmariah H, Pratz KW. Role of alternative donor allogeneic transplants in the therapy of acute myeloid leukemia. J Natl Compr Canc Netw. 2017;15:959–66.
doi: 10.6004/jnccn.2017.0119
Frassoni F, Labopin M, Powles R, Mary JY, Arcese W, Bacigalupo A, et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 2000;355:1393–8.
doi: 10.1016/S0140-6736(00)02137-1
Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013;31:1310–6.
doi: 10.1200/JCO.2012.44.3523
Shabbir-Moosajee M, Lombardi L, Ciurea SO. An overview of conditioning regimens for haploidentical stem cell transplantation with post-transplantation cyclophosphamide. Am J Hematol. 2015;90:541–8.
doi: 10.1002/ajh.23995
Ruggeri A, Labopin M, Sanz G, Piemontese S, Arcese W, Bacigalupo A, et al. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia. Leukemia. 2015;29:1891–900.
doi: 10.1038/leu.2015.98
Tanaka M, Miyamura K, Terakura S, Imai K, Uchida N, Ago H, et al. Comparison of cord blood transplantation with unrelated bone marrow transplantation in patients older than fifty years. Biol Blood Marrow Transplant. 2015;21:517–25.
doi: 10.1016/j.bbmt.2014.11.685
Rio B, Chevret S, Vigouroux S, Chevallier P, Furst S, Sirvent A, et al. Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial. Biol Blood Marrow Transplant. 2015;21:445–53.
doi: 10.1016/j.bbmt.2014.11.009
Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154–61.
doi: 10.1200/JCO.2016.70.7091
Terakura S, Kuwatsuka Y, Yamasaki S, Wake A, Kanda J, Inamoto Y, et al. GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia. Bone Marrow Transplant. 2017;52:1261–7.
doi: 10.1038/bmt.2017.116
Dahlberg A, Milano F. Cord blood transplantation: rewind to fast forward. Bone Marrow Transplant. 2017;52:799–802.
doi: 10.1038/bmt.2016.336
Barker JN, Kurtzberg J, Ballen K, Boo M, Brunstein C, Cutler C, et al. Optimal practices in unrelated donor cord blood transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2017;23:882–96.
doi: 10.1016/j.bbmt.2017.03.006
Sharma P, Pollyea DA, Smith CA, Purev E, Kamdar M, Haverkos B, et al. Thiotepa-based intensified reduced-intensity conditioning adult double-unit cord blood hematopoietic stem cell transplantation results in decreased relapse rate and improved survival compared with transplantation following standard reduced-intensity conditioning: a retrospective cohort comparison. Biol Blood Marrow Transplant. 2018;24:1671–7.
doi: 10.1016/j.bbmt.2018.04.019
Yamamoto H, Uchida N, Yuasa M, Kageyama K, Ota H, Kaji D, et al. A novel reduced-toxicity myeloablative conditioning regimen using full-dose busulfan, fludarabine, and melphalan for single cord blood transplantation provides durable engraftment and remission in nonremission myeloid malignancies. Biol Blood Marrow Transplant. 2016;22:1844–50.
doi: 10.1016/j.bbmt.2016.06.017